Blockbusters look set to grow

Three companies are looking to expand the market for their medications on the PBS, seeking additional indications in the March PBAC meeting, with blockbuster cancer drugs Opdivo and Keytruda leading the charge.

BMS is seeking to add a new indication for Opdivo, seeking to have it listed for "second-line squamous cell oesophageal carcinoma that have failed treatment with a fluoropyrimidine and platinum containing treatment regimen".

MSD has applied to expand the indications for blockbuster Keytruda, currently used for advanced renal cell carcinoma, to include advanced clear cell variant renal cell carcinoma.

To see the whole article, please login